- First Online:
- 270 Downloads
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. Compared with conventional antipsychotics, it has greater affinity for serotonin 5-HT2A than for dopamine D2 receptors.
In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment.
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology.
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. The most common adverse effects reported with olanzapine are bodyweight gain, somnolence, dizziness, anticholinergic effects (constipation and dry mouth) and transient asymptomatic liver enzyme elevations. In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in ≥3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine.
The high acquisition cost of olanzapine is offset by reductions in other treatment costs (inpatient and/or outpatient services) of schizophrenia. Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone.
Conclusions: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has binding affinity for a broad range of neurotransmitter receptors. It has significant in vitro inhibitory activity at dopamine D2, D3, D4, serotonin 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, histamine H1, α1-adrenergic and muscarinic receptors. The mixed receptor activity of olanzapine is similar to that of clozapine as is its greater affinity for serotonin 5-HT2A than dopamine D2 receptors.
In electrophysiological studies, olanzapine inhibited neuronal firing in the mesolimbic but not the nigrostriatal systems within the CNS, which may be predictive of a low potential for the induction of extrapyramidal symptoms (EPS).
Olanzapine is active in many animal behavioural models of antipsychotic activity. Inhibition of a number of dopamine and serotonin agonist-induced behaviours was demonstrated in vivo, confirming in vitro evidence of the receptor affinity profile of olanzapine. In animal models considered predictive of the potential to induce EPS, most studies indicated that olanzapine has less propensity than classical antipsychotics to induce these effects.
The absorption of olanzapine is extensive after oral administration in healthy volunteers and is unaffected by food. Plasma olanzapine concentrations increase proportionally with dosage, reaching a maximum at about 5 hours after administration.
The large volume of distribution (Vd), approximately 10 to 22 L/kg in healthy volunteers after a single oral dose, indicates the drug has broad tissue distribution. Olanzapine is highly (93%) protein bound in plasma, primarily to albumin and α1-acid glycoprotein. In vitro, about 5 to 14% of olanzapine (83% as unchanged drug) crosses the human placenta.
Olanzapine is extensively metabolised in the liver by uridine disphosphate glucuronyltransferase and the cytochrome P450-1A2 and -2D6 isoenzymes to the major metabolite 10-N-glucuronide and other inactive metabolites. Excretion of olanzapine and its metabolites is mainly in the urine (57%) and partly in the faeces (30%). The elimination half-life (t½β) of olanzapine is about 30 hours for young males and is prolonged in young female and elderly individuals. The total body clearance (CL) of olanzapine ranges from 12 to 47 L/h in healthy individuals, is decreased in the elderly and increased in smokers compared with nonsmokers.
Olanzapine pharmacokinetics were not significantly altered in different ethnic groups or in patients with renal or hepatic impairment although the combined effects of age, smoking and gender could lead to substantial pharmacokinetic differences in populations. Some cytochrome P450 isoenzyme inducers (e.g. carbamazapine) or inhibitors (e.g. fluvoxamine) also affect olanzapine pharmacokinetic parameters.
Olanzapine is more effective than placebo and at least as effective as haloperidol in the treatment of overall psychopathology symptoms as shown in a number of randomised double-blind trials in patients with schizophrenia and related psychoses.
In the largest trial (n = 1996), olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day for overall improvements in psychopathology as assessed by reductions in the Brief Psychiatric Rating Scale total score (33 vs 23%, p < 0.05), in the treatment of depressive symptoms as assessed by improvements in Montgomery-Åsberg Depression Rating Scale scores (36 vs 18%, p = 0.001) and in the treatment of negative symptoms as assessed by improvements in the Positive and Negative Syndrome Scale (PANSS) negative symptom scores (19 vs 13%, p < 0.05). Olanzapine was similar to haloperidol in effects on positive psychotic symptoms.
Olanzapine 10 to 20 mg/day was superior to placebo and olanzapine 5 to 20 mg/day was superior to haloperidol 5 to 20 mg/day in the maintenance therapy of schizophrenia. In pooled analyses of 1-year double-blind extensions of three 6-week acute phase studies, the risk of relapse (defined as rehospitalisation for psychopathology) was significantly lower for olanzapine than haloperidol recipients (20 vs 28%, p < 0.05).
In the first double-blind, multicentre, randomised trial in which 2 atypical antipsychotic agents have been compared in the treatment of schizophrenia, olanzapine 10 to 20 mg/day demonstrated superior efficacy compared with risperidone 4 to 12 mg/day against negative and depressive symptoms. No differential between-treatment effects were seen in the 28-week study (n = 339) on measures of overall psychotic symptoms, although treatment response (≥40% reduction from baseline PANSS total score) at end-point was seen in significantly more olanzapine-than risperidone-treated patients (37 vs 27%, p < 0.05). In contrast, preliminary results (reported as an abstract plus poster) from an 8-week double-blind, multicentre, randomised trial (n = 377) suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05). Consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.
Preliminary data from studies suggest that olanzapine improves cognitive deficits, as significant effects on some measures of executive function and verbal learning and memory were shown. Furthermore, improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. However, preliminary results from a comparative 8-week trial showed no significant between-treatment differences on any measures of cognitive performance with olanzapine or risperidone in patients with schizophrenia or schizoaffective disorder. Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. Post hoc analyses of comparator trials with haloperidol or risperidone demonstrated that the effect of olanzapine on depressive symptoms was significantly greater than that seen with either comparator drug.
Olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall efficacy in a post hoc analysis of a cohort with first-episode psychosis from a large double-blind trial, but was of similar efficacy to haloperidol 2 to 20 mg/day in preliminary results of a prospective double-blind evaluation in a larger population. Results from double-blind trials comparing olanzapine 5 to 25 mg/day and clozapine 25 to 600 mg/day or haloperidol 5 to 20 mg/day, suggested olanzapine is beneficial in some treatment-resistant patients. In these trials, olanzapine was similar in efficacy to clozapine and superior to haloperidol treatment. However, in one study of severely treatment-refractory patients, neither olanzapine 25 mg/day nor chlorpromazine 1200 mg/day was effective. Olanzapine has shown some efficacy in the treatment of children and adolescents as well as elderly patients with schizophrenia, although further studies are required to support these findings.
In placebo-controlled 6-week trials the most common adverse events (reported by at least 10% of olanzapine-treated patients) were somnolence, asthenia, agitation, headache, nervousness, insomnia, hostility, paranoid reaction, rhinitis, constipation, dizziness, anxiety and bodyweight gain. However, only somnolence, constipation and bodyweight gain occurred in a significantly higher incidence with olanzapine treatment than with placebo. In comparison with haloperidol, the incidence of dry mouth, bodyweight gain and increased appetite was significantly higher with olanzapine and compared with risperidone, the incidence of bodyweight gain was higher. In clinical trials, adverse event-related study withdrawal rates were similar between olanzapine, placebo and risperidone but were significantly lower with olanzapine than with haloperidol (5.5 vs 8.1%; pooled data from three 6-week trials).
There were no reports of clinically relevant abnormalities in haematological parameters (e.g. agranulocytosis), laboratory tests, vital signs or electrocardiogram results (including QT interval prolongation), in clinical studies of olanzapine. Orthostatic blood pressure changes were not clinically significant despite the number of reports of dizziness. Hepatic transaminase levels were clinically elevated in 2% of olanzapine recipients; however, the increases were transient and clinical signs of hepatotoxicity were not apparent. Olanzapine treatment was associated with dose-dependent rises in serum prolactin levels which were mild and transient and of lesser magnitude than those seen with haloperidol or risperidone.
Bodyweight gain in the range of approximately 2 to 3.5kg was associated with olanzapine treatment in 6-week clinical trials and was significantly higher than that seen with haloperidol or risperidone. In extension phases (for up to 3 years) of the acute phase trials, bodyweight gain appeared to plateau at around 40 weeks.
In clinical trials, the incidence of treatment-associated EPS, assessed by rating scales for parkinsonism, akathisia and dystonia, was comparable to that seen with placebo and significantly lower than that seen with haloperidol or risperidone, although the dosage of risperidone was higher than recommended in 1 trial. Indeed, improvements in existing symptoms were often noted with olanzapine. However, in 1 placebo-controlled trial, significant dose-related increases in spontaneously reported treatment-emergent EPS, particularly akathisia, were seen with olanzapine 2.5 to 17.5 mg/day. Treatment-emergent dyskinetic events were significantly lower with olanzapine than haloperidol or, in 1 trial, risperidone.
Pharmacoeconomic and Quality-of-Life Profile
Pharmacoeconomic comparisons of olanzapine and haloperidol generally suggest that olanzapine does not add to the overall treatment cost, and may even furnish small cost savings, in patients with schizophrenia and related disorders. The higher acquisition cost of olanzapine is counterbalanced by a reduction in inpatient and/or outpatient costs. Among 803 US patients participating in an international collaborative trial, mean total medical costs were $US388 (1995 values) per patient lower with olanzapine 5 to 20 mg/day than haloperidol 5 to 20 mg/day during the first 6 weeks of treatment. During the 46-week maintenance phase in 342 responding patients, total medical costs were $US636 per patient lower in the olanzapine group. Efficacy data from French patients in the same trial and a cost-effectiveness analysis of the data also favoured olanzapine. In a 5-year Markov model applied in various countries, olanzapine was more effective at a lower cost than haloperidol in 5 of 6 analyses; annual savings of approximately $US300 per patient were seen with olanzapine in most analyses. Olanzapine is more cost effective than haloperidol in modelled studies.
The daily acquisition cost for olanzapine at therapeutic dosages is 1.5- to 3.5-fold greater than that of risperidone, but most analyses of total medical costs and cost effectiveness have tended to favour olanzapine, although results were sensitive to changes in dosage levels. However, given that the differences have not been large, the reduction in medical resource costs (which offsets the higher drug acquisition cost of olanzapine) is clinically meaningful. In a prospective analysis, mean total per-patient costs were $US2843 (1997 values) lower with olanzapine 10 to 20 mg/day than with risperidone 4 to 12 mg/day in 150 evaluable US patients who completed a 28-week international study. In the 5-year Markov model, olanzapine was associated with slightly lower total costs ($US300 to $US500 per patient per year in most analyses) and similar effectiveness to risperidone. In a 1-year semi-Markov Belgian model, olanzapine produced slightly higher total costs than risperidone (1151 900 vs 1137 700 Belgian francs; 1998 values).
Treatment with olanzapine improves quality of life in patients with schizophrenia and related disorders. The extent of improvement tends to be greater than that with haloperidol treatment, and broadly similar to that with risperidone treatment.
Dosage and Administration
The recommended starting dosage of olanzapine is 5 to 10mg(1 to 5mg in elderly patients) once daily, regardless of meals. If clinically indicated, 5mg increments or decrements at intervals of at least 1 week may be implemented, up to a maximum recommended dosage of 15 mg/day. The effective dosage of olanzapine in clinical trials is in the range of 10 to 20 mg/day for most patients. Patients who respond to olanzapine should receive the lowest effective dosage for maintenance therapy, and treatment requirements should be reassessed periodically.
The risk of orthostatic hypotension can be minimised by dosage initiation at 5 mg/day followed by careful titration. Dosage modication should also be considered for patients who are debilitated or who may exhibit slower olanzapine metabolism (e.g. female patients who are nonsmokers and are aged ≥65 years). Olanzapine should be used with caution in patients with cardiovascular or cerebrovascular disease or any conditions which may predispose to the development of hypotension and in those with hepatic dysfunction or at risk of seizures. Somnolence is common with olanzapine and caution is advised if driving or operating machinery.
- 1.Bymaster F, Perry KW, Nelson DL, et al. Olanzapine: a basic science update. Br J Psychiatry 1999; 174 Suppl. 37: 36–40Google Scholar
- 7.Stephenson CME, Pilowsky LS. Psychopharmacology of olanzapine. A review. Br J Psychiatry 1999 May; 174 Suppl. 38: 52–8Google Scholar
- 8.Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 1997; 58 Suppl. 10: 28–36Google Scholar
- 10.Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996; 168 Suppl. 29: 23–31Google Scholar
- 11.Yanagida H, Morokawa Y, Morishima Y, et al. Relationship between the individuals differences in the plasma anti-serotonine activity to anti-dopamine activity ratio and manifestation of drug-induced extrapyramidal symptoms in serotonin-dopamine antagonist [abstract]. Int Clin Psychopharmacol 1999 Jan; 14: 48CrossRefGoogle Scholar
- 12.Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl. 10: 5–14Google Scholar
- 25.Deveney AM, Waddington JL. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective ‘D1-like’ dopamine receptor agonist A 68930 and selective ‘D2-like’ agonist RU 24213. Psychopharmacology 1996; 124: 40–9PubMedCrossRefGoogle Scholar
- 37.Moore NA, Leander JD, Benvenga MJ, et al. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 1997; 58 Suppl. 10: 37–44Google Scholar
- 41.Rossbach W, Mann K, Röschke J, et al. Effects of olanzapine on sleep EEG in schizophrenic patients [abstract]. Pharmacopsychiatry 1999 Sep; 32: 204Google Scholar
- 49.Bergstrom RF, Callaghan JT, Cerimele BJ, et al. Pharmacokinetics of olanzapine in elderly and young [abstract no. PPDM 8126]. Pharm Res 1995; 12 (9 Suppl.): S358Google Scholar
- 54.Eli Lilly and Company. Zyprexa (olanzapine) prescribing information. Indianapolis, USA, 2000Google Scholar
- 62.Demolle D, Onkelinx C, Müller-Oerlinghausen B. Interaction between olanzapine and lithium in healthy male volunteers [abstract no. 486]. Therapie 1995; 50 Suppl.Google Scholar
- 65.Mäenpää J, Wrightson S, Bergstrom R, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine [abstract]. Clin Pharmacol Ther 1997; 61(2): 225Google Scholar
- 70.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd revised ed. Washington, DC: American Psychiatric Association, 1987Google Scholar
- 71.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
- 75.Andreasen NC. Scale for the assessment of negative symptoms (SANS). Br J Psychiatry 1989; 155 Suppl. 7: 53–8Google Scholar
- 76.Guy W. ECDEU Assessment annual for Psychopharmacology: DHEW publication no (ADM) 76-338. Revised ed. Rockville (MD): National Institute of Mental Health, 1976Google Scholar
- 78.Janssen-Cilag Ltd. Haldol (haloperidol) prescribing information. Janssen-Cilag Ltd: Bucks, 1998Google Scholar
- 84.Perro C, Lambert M, Moritz S, et al. A comparison of clinical outcome of four atypical neuroleptics in the treatment of schizophrenia [abstract]. Pharmacopsychiatry 1999 Sep; 32: 201Google Scholar
- 85.Kolff M, Coenen A, van Dis H, et al. Differential effects of antipsychotic drugs on clinical symptoms and cognitive functions in the treatment of schizophrenia [abstract no. P.2.06]. Eur Neuropsychopharmacol 2000 April; 10 Suppl. 2: S59Google Scholar
- 87.Cantrell CK, Cole ES. New neuroleptics: an eight-year naturalistic study [abstract no. NR721]. New Research American Psychiatric Association 2000 Annual Meeting; 2000 May 13–18; Chicago (IL): 252Google Scholar
- 89.Loonen AJM, Loos JCM, Van Zonneveld TH. Comparisons of costs and effects of risperidone treatment versus olanzapine treatment in daily practice. New Research American Psychiatric Association 2000 Annual Meeting; 2000 May 13–18; Chicago (IL): 250–1Google Scholar
- 90.Conley RR, Mahmoud R, Risperidone Study Group. Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder [abstract no. P.01.219 plus poster]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S151Google Scholar
- 100.Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999; 60 Suppl. 10: 31–41Google Scholar
- 110.Kinon BJ, MIlton DR, Hill AL, et al. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine [abstract no. P.01.230 plus poster]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1Google Scholar
- 116.Hardoy MC, Cabras PL, Hardoy MJ, et al. Effects of olanzapine on neurocognition in schizophrenia [abstract no. PO-08-25]. 11th World Congress of Psychiatry 1999 Aug 6–11, Hamburg, Abstracts Vol. II: 153Google Scholar
- 120.Harvey PD. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder [abstract no. NR342]. New Research American Psychiatric Association Annual Meeting 2000 May 13–18; Chicago (IL): 149Google Scholar
- 121.Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry 1999; 60 Suppl. 10: 52–60Google Scholar
- 122.Wright P, Birkett K, Meehan S, et al. A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients [abstract no. P.01.173]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S139Google Scholar
- 123.Targum SD, Abbott JL. Psychoses in the elderly: a spectrum of disorders. J Clin Psychiatry 1999; 60 Suppl. 8: 4–10Google Scholar
- 124.Street J, Clark WS, Gannon KS, et al. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer’s disease [abstract no. P.4.039]. Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S331–332Google Scholar
- 127.Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry 1998; 59 Suppl. 12: 41–5Google Scholar
- 131.Martenyi F, Dossenbach M, Jakovljevic M, et al. Predictive value of early anti-anxiety effect on the acute-antipsychotic outcome; a comparison of fluphenazine and olanzapine [abstract no. NR382]. American Psychiatric Association Annual Meeting; 2000 May 13–18; Chicago, New Research Abstracts: 160–161Google Scholar
- 132.Cohen LS, Goldstein J, Tohen M, et al. Sex differences in response to treatment with olanzapine: a preliminary analysis [abstract]. Psychopharmacol Bull 1997; 33(3): 506Google Scholar
- 133.Tran P, Creanga D, Wang J, et al. Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent [abstract no. PO-16-40]. 11th World Congress of Psychiatry; 1999 Aug 6–11; Hamburg, Abstracts Vol. II: 173Google Scholar
- 134.Tran PV, Zhang F, Hwu H-G, et al. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong [abstract no. NR235]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington, DC, New Research Program & Abstracts: 129–30Google Scholar
- 135.Dossenbach M, Quraishi Z, Hussein M, et al. Olanzapine in a middle Asian patient population with acute schizophrenia [abstract no. PO-04-45]. 11th World Congress of Psychiatry 1999 Aug 6–11; Hamburg, Abstracts Vol II: 148Google Scholar
- 136.DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59 Suppl. 19: 9–17Google Scholar
- 137.Lieberman J, Perkins D, McEvoy JP, et al. Olanzapine vs Haloperidol on treatment of first-episode psychois: HGDH study group [poster]. Schizophrenia: across the life cycle. Annual Meeting of the American Psychiatric Association; May 2000; Chicago (IL)Google Scholar
- 140.Collaborative Working Group on Clinical Trial Evaluations. Treatment of special populations with the atypical antipsychotics. J Clin Psychiatry 1998; 59 Suppl. 12: 46–52Google Scholar
- 143.Tollefson GD, Birkett MA, Kiesler GM, et al. Double-Blind comparion of olanzapine versus clozapine in shizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. In pressGoogle Scholar
- 145.Bitter I, Slabber M, Pretorius J, et al. Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia [abstract no. P.01.182 plus poster]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S141Google Scholar
- 148.Dalack GW, Albucher RC, Carnahan J, et al. An open trial of olanzapine in poorly responsive psychosis [abstract no. 60]. Biol Psychiatry 1999 Apr 15; 45 Suppl.: 19SGoogle Scholar
- 149.Dossenbach MRK, Tollefson GD, Kratky P, et al. Olanzapine in patients non responsive or intolerant to risperidone [abstract]. Biol Psychiatry 1999 Apr 15; 45 Suppl.: 24SGoogle Scholar
- 158.Lindenmayer J-P, Volavka J, Lieberman JA, et al. Olanzapine in schizophrenia-refractory atypicals [abstract no. NR267]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 138–139Google Scholar
- 161.Baldacchino AM, Stubbs JH, Nevison-Andrews D. The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital. Pharm J 1998; 260(6980): 207–9Google Scholar
- 162.à Campo J, Nijman H, Merckelbach H. Olanzapine as medication of first choice in therapy resistant schizophrenia? Acta Neuropsychiatrica 1998; 10(3): 78–9Google Scholar
- 167.Mandoki MW. Olanzapine in the treatment of early onset schizophrenia in children and adolescents [abstract]. Biol Psychiatry 1997; 41 Suppl. 22: S37Google Scholar
- 173.Bulow K. Management of psychosis and agitation in elderly patients: a primary care perspective. J Clin Psychiatry 1999; 60 Suppl. 13: 22–5Google Scholar
- 174.Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer’s disease patients. Psychopharmacol Bull 1995; 31(3): 534Google Scholar
- 179.Verma SK, Orengo CA, Kunik ME, et al. Tolerability and efficacy of atypical antipsychotics in male geriatric inpatients [abstract no. NR64]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 78Google Scholar
- 180.Clark WR, Defilippi JL. Retrospective one-year review of the outcomes of atypical antipsychotic use at Central Texan Veterans Health Care System [abstract no. NR405]. New Research American Psychiatric Association Annual Meeting; 2000 May 13–18; Chicago (IL), 166Google Scholar
- 181.Frenchman IB, Pieniro M, Stenstrom S, et al. Comparison of atypical agents and haloperidol in nursing home patients [abstract no. NR506]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 208Google Scholar
- 182.Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58 Suppl. 10: 13–7Google Scholar
- 184.Schulz SC, Findling RL, Branicky LA, et al. Olanzapine in adolescents with a psychotic disorder. Schizophr Res 1999; 36: 297Google Scholar
- 187.Bergmans PLM, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Bulletin of the Menninger Clinic 1999; 63 (2 Suppl. A): A53–64Google Scholar
- 207.Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60 Suppl. 21: 20–4Google Scholar
- 211.Casey D. Weight and metabolic changes with clozapine and olanzapine [abstract no. NR339]. New Research American Psychiatric Association 2000 Annual Meeting; 2000 May 13–18; Chicago (IL), 148Google Scholar
- 212.Kinon B, Basson B, Szymonski K, et al. Factors associated with weight gain during olanzapine treatment [abstract no. PT07053]. XXIst Collegium Internationale Neuropsychopharmacologicum Congress; 1998 Jul 12–16; Glasgow, 329Google Scholar
- 215.Mulqueen AW, Wudarsky M, Nicolson RJ, et al. Weight gain in pediatric patients on typical and atypical antipsychotics [abstract no. NR552]. American Psychiatric Association Annual Meeting; 2000 May 13–18; Chicago, New Research Abstracts: 207Google Scholar
- 216.Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 Suppl. 10: 55–62Google Scholar
- 219.Gómez JC, Sacristán JA, Alvarez E, et al. Safety and effectiveness of olanzapine versus typical antipsychotic drugs in the treatment of inpatients with schizophrenia (EUROPA study) [abstract no. P.01.178 + poster]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S140Google Scholar
- 223.Kinon B, Basson BR, Stauffer V, et al. Effect of chronic olanzapine treatment on the course of presumptive tardive dyskinesia [abstract no. NR528]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 136Google Scholar
- 250.Glazer WM. Formulary decisions and health economics. J Clin Psychiatry 1998; 59 Suppl. 19: 23–9Google Scholar
- 251.Are patients with schizophrenia denied the best treatment? Pharm J 1998 Nov 28; 261: 847Google Scholar
- 261.Tunis SL, Johnstone BM, Gibson PJ, et al. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999; 60 Suppl. 19: 38–45Google Scholar
- 268.Spannheimer A, Clouth J. Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: a comparison of olanzapine and haloperidol [poster]. 11th World Congress of Psychiatry; 1999 Aug 6–11; Hamburg, Abstracts Vol. IIGoogle Scholar
- 269.Post HA, van HBA. Cost effectiveness of olanzapine in comparison to risperidone and haloperidol [abstract]. 13th Annual Meeting of the International Society of Technology Assessment in Health Care; 1997 May 25; Barcelona, 134Google Scholar
- 271.Gregor K, Jonsson L, Lindstrom E, et al. A cost-effectiveness clincial decision analysis for schizophrenia: results from Sweden [abstract no. PO-08-19]. 11th World Congress of Psychiatry; 1999 Aug 6–11; Hamburg, Abstracts Vol II: 152Google Scholar
- 274.Kasper S, Duchesne I, RODOS Investigator Group. RODOS: an international naturalistic study: final results [poster]. XXII CINP Congress; 2000 Jul 9–13; BrusselsGoogle Scholar
- 275.Rabinowitz J, Lichtenberg P, Kaplan Z. Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res. In pressGoogle Scholar
- 277.Laux G, Konig W. Risperidone and olanzapine drug use in a Bavarian district hospital [abstract]. Pharmacopsychiatry 1999 Sep; 32: 193Google Scholar
- 278.Kozma CM, Mody SH, Sadik MK. A comparative analysis of risperidone and olanzapine dosing patterns in the South Carolina Medicaid Program [abstractno. NR548]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 221Google Scholar
- 279.Gardner DM, Woodman A, Grasswick LJ, et al. Drug and resource use evaluation of risperidone and olanzapine in inpatients with outpatient follow-up [abstract no. NR661]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 255Google Scholar
- 281.Kelly DL, Nelson MW, Love RC, et al. Risperidone versus olanzapine: discharge rates and economic considerations [abstract no. NR554]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 223Google Scholar
- 282.Nasrallah H, Chan Y, Votolato NA. Higher cost of olanzapine compared to risperidone in acute psychotic relapse [abstract]. XXIst Collegium Internationale Neuro-psychopharmacologicum Congress; 1998 Jul 12–16; Glasgow, 290Google Scholar
- 283.Schwartz TL, Hardoby WJ, Saba M, et al. Use of atypical antipsychotics in a Veterans Affairs hospital [abstract no. NR120]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 95Google Scholar
- 285.Trenckmann U. Atypical neuroleptics in a German hospital [abstract no. PO.06-96]. 11th World Congress of Psychiatry; 1999 Aug 6–11; Hamburg, Abstracts Vol. II: 211Google Scholar
- 291.Del Paggio D, Singer RP. Efficacy and fiscal impact of atypical antipsychotics in county-wide outpatient managed care services [abstract no. NR605]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 238Google Scholar
- 292.Byerly MJ, Weber MT, Brooks D. Cost-effectiveness of risperidone versus olanzapine in schizophrenia: a computer database evaluation [abstract no. NR205]. American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington DC, New Research Program & Abstracts: 119Google Scholar
- 296.Tuynman-Qua HG, van Meer CR, de Roos V, et al. Subjective experience olanzapine, other antipsychotics [abstract no. PO-16-42]. 11th World Congress of Psychiatry 1999 Aug 6–11, Hamburg, Germany; Abstracts Vol. II: 173Google Scholar
- 297.Badia X, Casado A, Sacristán JA, et al. Antipsychotic treatment and changes in health related quality of life in patients with schizophrenia using EQ-5D [abstract no. P.01.180 + poster]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S141Google Scholar
- 299.British Medical Association. Olanzapine. BNF 2000: 180Google Scholar
- 300.Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58 Suppl. 10: 45–9Google Scholar
- 303.Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998; 59 Suppl. 3: 21–5Google Scholar
- 304.Herz MI, Liberman RP, McGlashan TH, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(4) Suppl.: 1–63Google Scholar
- 305.Mencacci C, Anniverno R, Durbano F. Improvement of psychosocial treatment with atypical antipsychotics [abstract no. B-76]. Eur Neuropsychopharmacol 1998 Mar; 8 Suppl. 1: S30Google Scholar
- 306.Angrist BM, Baldessarini RJ, Bowers MB, et al. Treatment of schizophrenia 1999. J Clin Psychiatry 1999; 60 Suppl. 11: 3–80Google Scholar